Evidence map›Paper›PMID 42050365›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Reduced risk of dementia with recombinant zoster vaccine in US adults age 65 or older.

Susan Dos Reis, Phuong Tran, Kareshma Mohanty, Alejandro Amill-Rosario, Abree Johnson, Kathleen Ryan, Hannah Alsdurf, Driss Oraichi, Huifeng Yun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Susan Dos ReisDepartment of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-2210-6650
Phuong TranDepartment of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
Kareshma MohantyDepartment of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
Alejandro Amill-RosarioDepartment of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
Abree JohnsonDepartment of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
Kathleen RyanDepartment of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
Hannah AlsdurfGlobal Vaccine and Infectious Disease Epidemiology, GSK, Rockville, Maryland, USA.
Driss OraichiGlobal Vaccine and Infectious Disease Epidemiology, GSK, Rockville, Maryland, USA.
Huifeng YunGlobal Vaccine and Infectious Disease Epidemiology, GSK, Rockville, Maryland, USA.

Funding

GSK
6 · The paper itself

Abstract

introductionHerpes zoster vaccines may lower the risk of dementia onset. We evaluated new-onset dementia among US Medicare beneficiaries ≥65 years old following recombinant zoster vaccination (RZV).

methodsWe matched one RZV-exposed to two RZV-unvaccinated on age, sex, and race/ethnicity. Individuals were ≥65 years old on the RZV dose 2 date (RZV-exposed) or preventive care visit date (RZV-unvaccinated), enrolled in Medicare ≥11 months before this date, and had no pre-existing dementia of any type. Weighted Cox proportional hazards models generated hazard ratios (HR) of new-onset dementia, Alzheimer's disease (AD), and vascular dementia (VD).

resultsThe incidence per 1000 person-years of new-onset dementia for 15,061/502,845 RZV-exposed and 36,526/1,005,690 RZV-unvaccinated was 10.45 and 15.73, respectively. Time-dependent HRs (95% confidence interval) for ≤3 and >3 years' follow-up were as follows: 0.67 (0.65, 0.68); 0.74 (0.69, 0.79) for dementia; 0.72 (0.69, 0.74); 0.83 (0.74, 0.94) for AD; 0.67 (0.64, 0.70); 0.66 (0.57, 0.78) for VD. DISCUSSION: Two-dose RZV may lower new-onset dementia, AD, and VD risk.

Indexed as

DementiaHerpes Zoster VaccineAgedAged, 80 and overAlzheimer DiseaseFemaleHumansIncidenceMaleMedicareProportional Hazards ModelsUnited StatesVaccines, SyntheticHerpes Zoster VaccineVaccines, SyntheticAlzheimer's diseasedementiaMedicarerecombinant zoster vaccine

Identifiers

PMID42050365
PMCPMC13124665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.